NO20065152L - Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav - Google Patents

Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav

Info

Publication number
NO20065152L
NO20065152L NO20065152A NO20065152A NO20065152L NO 20065152 L NO20065152 L NO 20065152L NO 20065152 A NO20065152 A NO 20065152A NO 20065152 A NO20065152 A NO 20065152A NO 20065152 L NO20065152 L NO 20065152L
Authority
NO
Norway
Prior art keywords
hmg
sustained
coa reductase
reductase inhibitor
release formulation
Prior art date
Application number
NO20065152A
Other languages
English (en)
Inventor
Jong-Soo Woo
Hong-Gi Yi
Moon-Hyuk Chi
Jae-Kuk Ryo
Si-Young Jung
Yong-Il Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of NO20065152L publication Critical patent/NO20065152L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En formulering med vedvarende frigivelse for oral administrering av en HMG-CoAreduktaseinhibitor ifølge den foreliggende oppfinnelse kan lett og økonomisk fremstilles, og er i stand til å opprettholde et konstant legemiddelnivå i blod ved å senke frigivelsen av HMG-CoA-reduktaseinhibitoren til en jevn grad i 24 timer. Følgelig kan formuleringen med vedvarende, frigivelse ifølge den foreliggende oppfinnelse effektivt anvendes for nedsettelse av blod-kolesterol og triglyseridnivåer.
NO20065152A 2004-04-10 2006-11-09 Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav NO20065152L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040024734A KR100598326B1 (ko) 2004-04-10 2004-04-10 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
PCT/KR2005/001021 WO2005097194A1 (en) 2004-04-10 2005-04-08 Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof

Publications (1)

Publication Number Publication Date
NO20065152L true NO20065152L (no) 2006-12-07

Family

ID=35124845

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065152A NO20065152L (no) 2004-04-10 2006-11-09 Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav

Country Status (15)

Country Link
US (1) US8475840B2 (no)
EP (1) EP1744782A4 (no)
JP (1) JP4740945B2 (no)
KR (1) KR100598326B1 (no)
CN (1) CN1946426B (no)
AU (1) AU2005230362B2 (no)
BR (1) BRPI0509710A8 (no)
CA (1) CA2562418C (no)
IL (1) IL178475A (no)
MX (1) MXPA06011517A (no)
NO (1) NO20065152L (no)
NZ (1) NZ550326A (no)
RU (1) RU2336903C2 (no)
WO (1) WO2005097194A1 (no)
ZA (1) ZA200609291B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521532A (ja) * 2005-12-27 2009-06-04 モノソル アールエックス リミテッド ライアビリティ カンパニー 活性物質を放出するための、ｐＨ調節されたフィルム
EP1825847A3 (en) * 2006-02-24 2008-01-23 Teva Pharmaceutical Industries Ltd Fluvastatin sodium pharmaceutical compositions
KR100791256B1 (ko) * 2006-03-17 2008-01-03 주식회사 대웅제약 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP1911441A3 (en) * 2006-10-11 2008-08-06 Lupin Limited Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
IS8612A (is) * 2007-02-19 2008-08-20 Actavis Group Ptc Ehf. Stöðugar statínlyfjasamsetningar
TR200800634A2 (tr) * 2008-01-30 2009-02-23 Takka Sevgi̇ Uzatılmış salım sağlayan fluvastatin tablet.
MX2010010050A (es) 2008-03-20 2011-03-15 Virun Inc Star Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
ES2664729T3 (es) * 2009-12-30 2018-04-23 Bcworld Pharm. Co. Ltd. Composición farmacéutica que comprende metformina y rosuvastatina
CN103037708B (zh) * 2010-03-23 2015-05-20 维尔恩公司 含有蔗糖脂肪酸酯的纳米乳液
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
WO2022129003A1 (en) * 2020-12-15 2022-06-23 Dsm Ip Assets B.V. Multiparticulate solid oral dosage form comprising statin and vitamin e

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (no) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
CA2045428A1 (en) 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
CA2309597A1 (en) * 1997-11-10 1999-05-20 Hiroshi Sorimachi Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
AU4943400A (en) * 2000-06-09 2001-12-17 Lek Tovarna Farmacevtskih Stabilized pharmaceutically effective composition and pharmaceutical formulationcomprising the same
JP2001233766A (ja) 2000-11-15 2001-08-28 Ohara Yakuhin Kogyo Kk プラバスタチンナトリウムの錠剤
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
KR100548925B1 (ko) * 2002-10-23 2006-02-02 한미약품 주식회사 약물의 경구투여용 서방성 조성물

Also Published As

Publication number Publication date
MXPA06011517A (es) 2007-01-16
RU2006139748A (ru) 2008-05-20
ZA200609291B (en) 2008-05-28
JP2007532532A (ja) 2007-11-15
US20070196480A1 (en) 2007-08-23
EP1744782A1 (en) 2007-01-24
NZ550326A (en) 2010-08-27
AU2005230362A1 (en) 2005-10-20
IL178475A0 (en) 2007-02-11
CN1946426B (zh) 2010-06-16
BRPI0509710A8 (pt) 2016-06-07
WO2005097194A1 (en) 2005-10-20
CN1946426A (zh) 2007-04-11
AU2005230362B2 (en) 2007-10-18
US8475840B2 (en) 2013-07-02
JP4740945B2 (ja) 2011-08-03
CA2562418A1 (en) 2005-10-20
EP1744782A4 (en) 2011-02-16
CA2562418C (en) 2009-02-10
RU2336903C2 (ru) 2008-10-27
KR100598326B1 (ko) 2006-07-10
IL178475A (en) 2014-03-31
KR20050099583A (ko) 2005-10-13
BRPI0509710A (pt) 2007-09-18

Similar Documents

Publication Publication Date Title
NO20065152L (no) Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav
TNSN08534A1 (en) Modulators of metabolism and the treatment of disorders related thereto
EA200970359A1 (ru) Статин и омега-3 жирные кислоты для снижения уровней аро-в
DE602006006461D1 (de) Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
NZ711283A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
EA200970088A1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
KR102668887B1 (ko) 암, 자가면역 장애, 및 만성 염증과 관련된 다른 병태를 치료하는 방법
LU91933I2 (fr) 4-aminopyridine et ses dérivés
TNSN04136A1 (en) Aza-arylpiperazines
WO2007140005A3 (en) Oxazolyl piperidine modulators of fatty acid amide hydrolase
GEP20125684B (en) Dipeptidyl peptidase inhibitors weekly administration
WO2007048220A3 (en) Trazodone composition for once a day adminisitiation
WO2013083286A1 (en) TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
GEP20125570B (en) Use of indazolemethoxyalkanoic acid for reducing levels of triglycerides, cholesterol and glucose
NO20064642L (no) Anvendelse av (S,S)- eller racemisk reboxetin
WO2005058341A3 (en) Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
WO2005065664A8 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
WO2005051937A8 (en) 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
AU2003270292A1 (en) Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS

FC2A Withdrawal, rejection or dismissal of laid open patent application